Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    James Marks, MD, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentAnesthesia
    Address1001 Potrero Ave, SFGH 1
    San Francisco CA 94110
    Phone415-206-3256
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San Francisco Residency School of Medicine
      University of California, San FranciscoM.D. School of Medicine1979

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse Awarded Grants
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis. 2016 May 15; 213(10):1606-14. PMID: 26936913.
        View in: PubMed
      2. Krombach JW, Marks JD, Dubowitz G, Radke OC. Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety. Anesth Analg. 2015 Oct; 121(4):1097-103. PMID: 26378706.
        View in: PubMed
      3. Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5. Mol Cancer Ther. 2015 Nov; 14(11):2595-605. PMID: 26358753.
        View in: PubMed
      4. Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel). 2015 Sep; 7(9):3405-23. PMID: 26343720; PMCID: PMC4591640.
      5. Krombach JW, Edwards WA, Marks JD, Radke OC. Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution. Anesth Pain Med. 2015 Aug; 5(4):e26300. PMID: 26568921.
        View in: PubMed
      6. Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia. 2016 Mar; 30(3):692-700. PMID: 26286117.
        View in: PubMed
      7. Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One. 2015; 10(8):e0135306. PMID: 26275214; PMCID: PMC4537209.
      8. Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL. TGF-ß-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. J Immunol. 2015 Aug 1; 195(3):1182-90. PMID: 26109638; PMCID: PMC4506848 [Available on 08/01/16].
      9. Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel. 2015 Oct; 28(10):307-16. PMID: 25991864; PMCID: PMC4607741 [Available on 10/01/16].
      10. Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL. Transforming Growth Factor-ß and Interleukin-1ß Signaling Pathways Converge on the Chemokine CCL20 Promoter. J Biol Chem. 2015 Jun 5; 290(23):14717-28. PMID: 25918170; PMCID: PMC4505537 [Available on 06/05/16].
      11. D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One. 2014; 9(11):e112376. PMID: 25386657; PMCID: PMC4227695.
      12. Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y. High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One. 2014; 9(10):e111339. PMID: 25353955; PMCID: PMC4213037.
      13. Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17. PMID: 25143449; PMCID: PMC4221648.
      14. Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM. Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins. Analyst. 2014 Oct 21; 139(20):5093-102. PMID: 25112421.
        View in: PubMed
      15. Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks JD, Wu AM. Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation. Protein Eng Des Sel. 2014 Oct; 27(10):317-24. PMID: 25095796; PMCID: PMC4191443.
      16. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL. Selective targeting of TGF-ß activation to treat fibroinflammatory airway disease. Sci Transl Med. 2014 Jun 18; 6(241):241ra79. PMID: 24944194; PMCID: PMC4341974.
      17. Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014 May; 9(5):664-74. PMID: 24644233; PMCID: PMC4073886.
      18. Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014 Apr 2; 588(7):1087-93. PMID: 24583011; PMCID: PMC4067265.
      19. Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S. RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Talanta. 2013 Dec 15; 117:273-80. PMID: 24209341; PMCID: PMC3909959.
      20. Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 2013 Jul 1; 453(1):37-47. PMID: 23621114.
        View in: PubMed
      21. Jones RG, Marks JD. Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol. 2013 Jun; 62(Pt 6):828-35. PMID: 23518650.
        View in: PubMed
      22. Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD, Denny CT. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906. PMID: 23024593; PMCID: PMC3447386.
      23. Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM. Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem. 2012 Nov 15; 430(2):185-92. PMID: 22935296; PMCID: PMC3589981.
      24. Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012 Nov 15; 430(2):141-50. PMID: 22922799; PMCID: PMC4209713.
      25. Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB. N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano. 2012 Aug 28; 6(8):6675-80. PMID: 22830952; PMCID: PMC3435507.
      26. McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun; 14(3):336-47. PMID: 21630083; PMCID: PMC3227780.
      27. Zhou Y, Zhao L, Marks JD. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys. 2012 Oct 15; 526(2):107-13. PMID: 22627065; PMCID: PMC4209712.
      28. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul; 11(7):1467-76. PMID: 22564724; PMCID: PMC4209485.
      29. Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG. A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem. 2012 Jun 1; 425(1):28-35. PMID: 22406430.
        View in: PubMed
      30. Zhou Y, Marks JD. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol. 2012; 502:43-66. PMID: 22208981; PMCID: PMC4180867.
      31. Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012; 502:139-66. PMID: 22208985.
        View in: PubMed
      32. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012 Jan; 11(1):143-53. PMID: 22090420.
        View in: PubMed
      33. Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem. 2011; 12:58. PMID: 22085466; PMCID: PMC3250939.
      34. Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem. 2011 Dec 23; 286(51):44218-33. PMID: 22002064; PMCID: PMC3243554.
      35. Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem. 2012 Feb 15; 421(2):351-61. PMID: 22037290; PMCID: PMC4209596.
      36. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin avß8-mediated activation of TGF-ß. J Clin Invest. 2011 Jul; 121(7):2863-75. PMID: 21646718; PMCID: PMC3223836.
      37. Gray SA, Barr JR, Kalb SR, Marks JD, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ. Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes. Biotechnol Bioeng. 2011 Oct; 108(10):2456-67. PMID: 21538339; PMCID: PMC3203252.
      38. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011 Mar 15; 71(6):2250-9. PMID: 21406401; PMCID: PMC3077882.
      39. Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011 Mar 15; 17(6):1509-20. PMID: 21177408; PMCID: PMC3060271.
      40. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel. 2011 Mar; 24(3):321-31. PMID: 21149386; PMCID: PMC3038462.
      41. Zhou Y, Zou H, Zhang S, Marks JD. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol. 2010 Nov 19; 404(1):88-99. PMID: 20851130; PMCID: PMC4195448.
      42. Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One. 2010; 5(8):e12237. PMID: 20808925; PMCID: PMC2923190.
      43. Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res. 2010; 2(4):368-80. PMID: 20733947; PMCID: PMC2923861.
      44. Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010 Jul 1; 70(13):5497-506. PMID: 20530676.
        View in: PubMed
      45. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug; 37(8):1529-38. PMID: 20354850; PMCID: PMC2903645.
      46. Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks JD. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel. 2010 Apr; 23(4):311-9. PMID: 20156888; PMCID: PMC2841544.
      47. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer Res. 2010 Feb 15; 70(4):1505-12. PMID: 20145119; PMCID: PMC2823079.
      48. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010 Apr 9; 397(4):1106-18. PMID: 20138889; PMCID: PMC2903050.
      49. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res. 2009 Dec 1; 69(23):8987-95. PMID: 19934334.
        View in: PubMed
      50. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 4; 141(1):13-21. PMID: 19686789.
        View in: PubMed
      51. Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun. 2009 Oct; 77(10):4305-13. PMID: 19651864; PMCID: PMC2747958.
      52. Ozanich RM, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks JD, Lou J, Grate JW. Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem. 2009 Jul 15; 81(14):5783-93. PMID: 19530657.
        View in: PubMed
      53. Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks JD, Bruckner-Lea CJ. Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron. 2009 Sep 15; 25(1):179-84. PMID: 19643593; PMCID: PMC2728038.
      54. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One. 2009; 4(4):e5355. PMID: 19399171; PMCID: PMC2670495.
      55. Grate JW, Warner MG, Ozanich RM, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC, Lind MA, Lou J, Marks JD, Bruckner-Lea CJ. Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format. Analyst. 2009 May; 134(5):987-96. PMID: 19381395.
        View in: PubMed
      56. Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl). 2009 May; 87(5):507-14. PMID: 19219419; PMCID: PMC2796542.
      57. Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol. 2009 Sep; 64(4):741-51. PMID: 19184019; PMCID: PMC2717390.
      58. Zhou Y, Marks JD. Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol. 2009; 525:145-60, xv. PMID: 19252832.
        View in: PubMed
      59. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol. 2009; 525:1-27, xiii. PMID: 19252861; PMCID: PMC3402212.
      60. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res. 2008 Nov 15; 14(22):7367-77. PMID: 19010852; PMCID: PMC3109074.
      61. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 4; 99(9):1415-25. PMID: 18841159; PMCID: PMC2576487.
      62. Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW. Development of human single-chain antibodies against SARS-associated coronavirus. Intervirology. 2008; 51(3):173-81. PMID: 18724064.
        View in: PubMed
      63. Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 1; 14(3):875-82. PMID: 18245551; PMCID: PMC2643368.
      64. Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks JD, Xie G, Brettin TS. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One. 2007; 2(12):e1271. PMID: 18060065; PMCID: PMC2092393.
      65. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M. Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem. 2008 Feb 15; 283(7):3997-4003. PMID: 18032388.
        View in: PubMed
      66. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007 Oct; 6(10):2737-46. PMID: 17938267.
        View in: PubMed
      67. Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007 Oct; 30(7):684-93. PMID: 17893561.
        View in: PubMed
      68. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol. 2007 Dec; 81(23):13149-57. PMID: 17804513; PMCID: PMC2169077.
      69. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007 Sep 1; 179(5):2815-23. PMID: 17709495.
        View in: PubMed
      70. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl). 2007 Oct; 85(10):1113-23. PMID: 17554518.
        View in: PubMed
      71. Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007 Aug 24; 371(4):934-47. PMID: 17602702; PMCID: PMC4198021.
      72. Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol. 2007 Jul; 44(15):3777-88. PMID: 17498801; PMCID: PMC2739904.
      73. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007 Jan; 25(1):107-16. PMID: 17173035.
        View in: PubMed
      74. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol. 2007 Feb; 189(3):818-32. PMID: 17114256; PMCID: PMC1797315.
      75. Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N, Park JW, Marks JD, Benz CC, Kirpotin DB. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm. 2006 Nov-Dec; 3(6):726-36. PMID: 17140260.
        View in: PubMed
      76. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol. 2007 Jan 5; 365(1):196-210. PMID: 17059824; PMCID: PMC1994578.
      77. Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD. A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol. 2006; 7:24. PMID: 17014727; PMCID: PMC1633733.
      78. Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks JD, Bertozzi CR, Bradbury AR. Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics. 2006 Dec; 5(12):2350-63. PMID: 16971384.
        View in: PubMed
      79. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol. 2006 Sep 29; 362(4):733-42. PMID: 16938310.
        View in: PubMed
      80. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006 Jul 1; 66(13):6732-40. PMID: 16818648.
        View in: PubMed
      81. Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ. Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Anal Chim Acta. 2006 Jun 16; 570(2):137-43. PMID: 17723391.
        View in: PubMed
      82. Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta. 2006 Apr; 1758(4):429-42. PMID: 16678786.
        View in: PubMed
      83. Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther. 2006 Apr; 13(7):646-51. PMID: 16341056.
        View in: PubMed
      84. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006 Mar 1; 12(5):1599-605. PMID: 16533787.
        View in: PubMed
      85. Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm. 2005 Dec; 20(6):603-13. PMID: 16398612.
        View in: PubMed
      86. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005 Sep; 73(9):5450-7. PMID: 16113261; PMCID: PMC1231122.
      87. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol. 2005 Aug 5; 351(1):158-69. PMID: 16002090.
        View in: PubMed
      88. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005 Feb 15; 65(4):1471-8. PMID: 15735035.
        View in: PubMed
      89. Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog. 2005 Jan-Feb; 21(1):221-32. PMID: 15903261.
        View in: PubMed
      90. Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog. 2005 Jan-Feb; 21(1):205-20. PMID: 15903260.
        View in: PubMed
      91. Manoutcharian K, Acero G, Munguia ME, Becerril B, Massieu L, Govezensky T, Ortiz E, Marks JD, Cao C, Ugen K, Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiol Dis. 2004 Oct; 17(1):114-21. PMID: 15350972.
        View in: PubMed
      92. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 2004 Sep 1; 64(17):6200-6. PMID: 15342405.
        View in: PubMed
      93. Marks JD. Medical aspects of biologic toxins. Anesthesiol Clin North America. 2004 Sep; 22(3):509-32, vii. PMID: 15325716.
        View in: PubMed
      94. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004 Aug; 8(4):335-53. PMID: 15268628.
        View in: PubMed
      95. Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004 Jul; 290(1-2):29-49. PMID: 15261570.
        View in: PubMed
      96. Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, Foster KA. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods. 2004 May; 288(1-2):55-60. PMID: 15183085.
        View in: PubMed
      97. Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ. Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett. 2004 Apr 23; 564(1-2):24-34. PMID: 15094038.
        View in: PubMed
      98. Marks JD. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord. 2004 Mar; 19 Suppl 8:S101-8. PMID: 15027061.
        View in: PubMed
      99. Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks JD, Santoro C. Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. J Immunol Methods. 2004 Feb 1; 285(1):99-109. PMID: 14871539.
        View in: PubMed
      100. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10. PMID: 14744788.
        View in: PubMed
      101. Marks JD. Antibody affinity maturation by chain shuffling. Methods Mol Biol. 2004; 248:327-43. PMID: 14970506.
        View in: PubMed
      102. Marks JD, Bradbury A. PCR cloning of human immunoglobulin genes. Methods Mol Biol. 2004; 248:117-34. PMID: 14970493.
        View in: PubMed
      103. Marks JD, Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol Biol. 2004; 248:161-76. PMID: 14970495.
        View in: PubMed
      104. Marks JD. Selection of internalizing antibodies for drug delivery. Methods Mol Biol. 2004; 248:201-8. PMID: 14970498.
        View in: PubMed
      105. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15; 63(12):3154-61. PMID: 12810643.
        View in: PubMed
      106. Pavlik P, Siegel RW, Marzari R, Sblattero D, Verzillo V, Collins C, Marks JD, Bradbury A. Predicting antigenic peptides suitable for the selection of phage antibodies. Hum Antibodies. 2003; 12(4):99-112. PMID: 15156098.
        View in: PubMed
      107. Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol. 2002 Oct; 32(10):2773-82. PMID: 12355429.
        View in: PubMed
      108. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002 Aug 19; 1591(1-3):109-118. PMID: 12183061.
        View in: PubMed
      109. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11346-50. PMID: 12177434; PMCID: PMC123259.
      110. O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol. 2002 Aug 2; 321(1):49-56. PMID: 12139932.
        View in: PubMed
      111. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002 Jul 1; 186(1):64-73. PMID: 12089663.
        View in: PubMed
      112. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002 Apr; 8(4):1172-81. PMID: 11948130.
        View in: PubMed
      113. Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002 Mar 15; 317(1):73-83. PMID: 11916379.
        View in: PubMed
      114. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002 Feb 22; 20(11-12):1640-8. PMID: 11858873.
        View in: PubMed
      115. Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol. 2002 Feb 1; 315(5):1063-73. PMID: 11827476.
        View in: PubMed
      116. Lindquist EA, Marks JD, Kleba BJ, Stephens RS. Phage-display antibody detection of Chlamydia trachomatis-associated antigens. Microbiology. 2002 Feb; 148(Pt 2):443-51. PMID: 11832508.
        View in: PubMed
      117. Mullaney BP, Pallavicini MG, Marks JD. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun. 2001 Oct; 69(10):6511-4. PMID: 11553596; PMCID: PMC98787.
      118. Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther. 2001 Aug; 8(8):555-65. PMID: 11571533.
        View in: PubMed
      119. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001 Jul 6; 74(1-3):95-113. PMID: 11489487.
        View in: PubMed
      120. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001 Jun 15; 61(12):4750-5. PMID: 11406547.
        View in: PubMed
      121. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 2001 May 15; 166(10):6112-7. PMID: 11342630.
        View in: PubMed
      122. Sheridan RE, Deshpande SS, Amersdorfer P, Marks JD, Smith T. Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. Toxicon. 2001 May; 39(5):651-7. PMID: 11072043.
        View in: PubMed
      123. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods. 2001 May 1; 251(1-2):123-35. PMID: 11292488.
        View in: PubMed
      124. Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks JD. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2682-7. PMID: 11226299; PMCID: PMC30198.
      125. Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods. 2001 Feb 1; 248(1-2):17-30. PMID: 11223066.
        View in: PubMed
      126. Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun. 2001 Jan 12; 280(1):274-9. PMID: 11162510.
        View in: PubMed
      127. Kallet RH, Siobal MS, Alonso JA, Warnecke EL, Katz JA, Marks JD. Lung collapse during low tidal volume ventilation in acute respiratory distress syndrome. Respir Care. 2001 Jan; 46(1):49-52. PMID: 11175238.
        View in: PubMed
      128. Marshall KW, Marks JD. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells. J Immunother. 2001 Jan-Feb; 24(1):27-36. PMID: 11211146.
        View in: PubMed
      129. Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000 Nov 15; 60(22):6434-40. PMID: 11103810.
        View in: PubMed
      130. Liu B, Marks JD. Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem. 2000 Nov 1; 286(1):119-28. PMID: 11038282.
        View in: PubMed
      131. Siegel RW, Allen B, Pavlik P, Marks JD, Bradbury A. Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics. J Mol Biol. 2000 Sep 15; 302(2):285-93. PMID: 10970733.
        View in: PubMed
      132. Kallet RH, Katz JA, Pittet JF, Ghermey J, Siobal M, Alonso JA, Marks JD. Measuring intra-esophageal pressure to assess transmural pulmonary arterial occlusion pressure in patients with acute lung injury: a case series and review. Respir Care. 2000 Sep; 45(9):1072-84. PMID: 10980099.
        View in: PubMed
      133. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000 Sep 1; 301(5):1149-61. PMID: 10966812.
        View in: PubMed
      134. Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol. 2000 May; 27(4):339-46. PMID: 10938467.
        View in: PubMed
      135. Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med. 2000 Apr; 161(4 Pt 1):1149-53. PMID: 10764304.
        View in: PubMed
      136. Katz JA, Kallet RH, Alonso JA, Marks JD. Improved flow and pressure capabilities of the Datex-Ohmeda SmartVent anesthesia ventilator. J Clin Anesth. 2000 Feb; 12(1):40-7. PMID: 10773507.
        View in: PubMed
      137. Eberhard LW, Morabito DJ, Matthay MA, Mackersie RC, Campbell AR, Marks JD, Alonso JA, Pittet JF. Initial severity of metabolic acidosis predicts the development of acute lung injury in severely traumatized patients. Crit Care Med. 2000 Jan; 28(1):125-31. PMID: 10667511.
        View in: PubMed
      138. Amersdorfer P, Marks JD. Phage libraries for generation of anti-botulinum scFv antibodies. Methods Mol Biol. 2000; 145:219-40. PMID: 10820725.
        View in: PubMed
      139. Hughes-Jones NC, Bye JM, Gorick BD, Marks JD, Ouwehand WH. Synthesis of Rh Fv phage-antibodies using VH and VL germline genes. Br J Haematol. 1999 Jun; 105(3):811-6. PMID: 10354152.
        View in: PubMed
      140. Cirino NM, Sblattero D, Allen D, Peterson SR, Marks JD, Jackson PJ, Bradbury A, Lehnert BE. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun. 1999 Jun; 67(6):2957-63. PMID: 10338505; PMCID: PMC96606.
      141. McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999 May; 36(7):433-45. PMID: 10449096.
        View in: PubMed
      142. Poul MA, Marks JD. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 1999 Apr 30; 288(2):203-11. PMID: 10329137.
        View in: PubMed
      143. Becerril B, Poul MA, Marks JD. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun. 1999 Feb 16; 255(2):386-93. PMID: 10049718.
        View in: PubMed
      144. McCall AM, Amoroso AR, Sautès C, Marks JD, Weiner LM. Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries. Immunotechnology. 1998 Jun; 4(1):71-87. PMID: 9661816.
        View in: PubMed
      145. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD, Lindqvist E. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A. 1998 May 26; 95(11):6157-62. PMID: 9600934; PMCID: PMC27609.
      146. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998 May; 77(9):1405-12. PMID: 9652755; PMCID: PMC2150193.
      147. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998 Apr; 26(4):676-84. PMID: 9559604.
        View in: PubMed
      148. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998 Feb 1; 58(3):485-90. PMID: 9458094.
        View in: PubMed
      149. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun. 1997 Sep; 65(9):3743-52. PMID: 9284147; PMCID: PMC175534.
      150. Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun. 1997 May; 65(5):1626-30. PMID: 9125539; PMCID: PMC175186.
      151. Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks JD, Lockwood CM, Ouwehand WH. Human autoimmune anti-proteinase 3 scFv from a phage display library. Clin Exp Immunol. 1997 Feb; 107(2):269-81. PMID: 9030863; PMCID: PMC1904567.
      152. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996 Nov 8; 263(4):551-67. PMID: 8918938.
        View in: PubMed
      153. Marks C, Marks JD. Phage libraries--a new route to clinically useful antibodies. N Engl J Med. 1996 Sep 5; 335(10):730-3. PMID: 8703174.
        View in: PubMed
      154. Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene. 1996 Mar 9; 169(2):147-55. PMID: 8647439.
        View in: PubMed
      155. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol. 1996 Jan 12; 255(1):28-43. PMID: 8568873.
        View in: PubMed
      156. Schier R, Marks JD. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas. 1996; 7(3):97-105. PMID: 9057057.
        View in: PubMed
      157. Finnern R, Bye JM, Dolman KM, Zhao MH, Short A, Marks JD, Lockwood MC, Ouwehand WH. Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries. Clin Exp Immunol. 1995 Dec; 102(3):566-74. PMID: 8536374; PMCID: PMC1553387.
      158. Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995 May; 1(1):73-81. PMID: 9373335.
        View in: PubMed
      159. Hughes-Jones NC, Gorick BD, Bye JM, Finnern R, Scott ML, Voak D, Marks JD, Ouwehand WH. Characterization of human blood group scFv antibodies derived from a V gene phage-display library. Br J Haematol. 1994 Sep; 88(1):180-6. PMID: 7803241.
        View in: PubMed
      160. Figini M, Marks JD, Winter G, Griffiths AD. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J Mol Biol. 1994 May 27; 239(1):68-78. PMID: 8196048.
        View in: PubMed
      161. Ouwehand WH, Bye JM, Gorick BD, Marks JD, Timmers E, Griffin HM, Finnern R, Hughes-Jones N. The humoral immune response against blood group antigens at the molecular level. Vox Sang. 1994; 67 Suppl 3:7-12. PMID: 7975514.
        View in: PubMed
      162. Stackhouse RA, Marks JD, Bainton CR. Performing fiberoptic endotracheal intubation: clinical aspects. Int Anesthesiol Clin. 1994; 32(4):57-73. PMID: 7875909.
        View in: PubMed
      163. Marks JD. Fiberoptic-aided endobronchial intubation. Int Anesthesiol Clin. 1994; 32(4):75-84. PMID: 7875910.
        View in: PubMed
      164. Marks JD, Bainton CR. Practical aspects of fiberoptic laryngobronchoscopy. Int Anesthesiol Clin. 1994; 32(4):31-46. PMID: 7875907.
        View in: PubMed
      165. Marks JD, Ouwehand WH, Bye JM, Finnern R, Gorick BD, Voak D, Thorpe SJ, Hughes-Jones NC, Winter G. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (N Y). 1993 Oct; 11(10):1145-9. PMID: 7764095.
        View in: PubMed
      166. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 1993 Feb; 12(2):725-34. PMID: 7679990; PMCID: PMC413258.
      167. Bye JM, Carter C, Cui Y, Gorick BD, Songsivilai S, Winter G, Hughes-Jones NC, Marks JD. Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift. J Clin Invest. 1992 Dec; 90(6):2481-90. PMID: 1469099; PMCID: PMC443405.
      168. Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Immunol Rev. 1992 Dec; 130:41-68. PMID: 1286871.
        View in: PubMed
      169. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol. 1992 Oct 5; 227(3):776-98. PMID: 1404388.
        View in: PubMed
      170. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. Structural repertoire of the human VH segments. J Mol Biol. 1992 Oct 5; 227(3):799-817. PMID: 1404389.
        View in: PubMed
      171. Marks JD, Hoogenboom HR, Griffiths AD, Winter G. Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J Biol Chem. 1992 Aug 15; 267(23):16007-10. PMID: 1644788.
        View in: PubMed
      172. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y). 1992 Jul; 10(7):779-83. PMID: 1368267.
        View in: PubMed
      173. Marks JD, Winter G. An artificial immune system for making antibodies. Behring Inst Mitt. 1992 Apr; (91):6-12. PMID: 1524572.
        View in: PubMed
      174. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991 Dec 5; 222(3):581-97. PMID: 1748994.
        View in: PubMed
      175. Hastings RH, Marks JD. Airway management for trauma patients with potential cervical spine injuries. Anesth Analg. 1991 Oct; 73(4):471-82. PMID: 1897772.
        View in: PubMed
      176. Marks JD, Tristem M, Karpas A, Winter G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur J Immunol. 1991 Apr; 21(4):985-91. PMID: 2019291.
        View in: PubMed
      177. Songsivilai S, Bye JM, Marks JD, Hughes-Jones NC. Cloning and sequencing of human lambda immunoglobulin genes by the polymerase chain reaction. Eur J Immunol. 1990 Dec; 20(12):2661-6. PMID: 2125272.
        View in: PubMed
      178. Biery DR, Marks JD, Schapera A, Autry M, Schlobohm RM, Katz JA. Factors affecting perioperative pulmonary function in acute respiratory failure. Chest. 1990 Dec; 98(6):1455-62. PMID: 2123151.
        View in: PubMed
      179. Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest. 1990 Aug; 86(2):474-80. PMID: 2384595; PMCID: PMC296749.
      180. Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan; 141(1):94-7. PMID: 2297191.
        View in: PubMed
      181. Marks JD, Schapera A, Kraemer RW, Katz JA. Pressure and flow limitations of anesthesia ventilators. Anesthesiology. 1989 Sep; 71(3):403-8. PMID: 2672901.
        View in: PubMed
      182. Schapera A, Marks JD, Minagi H, Goodman P, Katz JA. Perioperative pulmonary function in acute respiratory failure: effect of ventilator type and gas mixture. Anesthesiology. 1989 Sep; 71(3):396-402. PMID: 2774267.
        View in: PubMed
      183. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988 Jul; 138(1):62-8. PMID: 3202402.
        View in: PubMed
      184. Hansen RM, Viquerat CE, Matthay MA, Wiener-Kronish JP, DeMarco T, Bahtia S, Marks JD, Botvinick EH, Chatterjee K. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery. Anesthesiology. 1986 Jun; 64(6):764-70. PMID: 3487261.
        View in: PubMed
      185. Katz JA, Marks JD. Inspiratory work with and without continuous positive airway pressure in patients with acute respiratory failure. Anesthesiology. 1985 Dec; 63(6):598-607. PMID: 3904528.
        View in: PubMed
      186. Marks JD, Luce JM, Lazar NM, Wu JN, Lipavsky A, Murray JF. Effect of increases in lung volume on clearance of aerosolized solute from human lungs. J Appl Physiol (1985). 1985 Oct; 59(4):1242-8. PMID: 3902778.
        View in: PubMed
      187. MARKS JD, ROESKY N, CARVER MJ. The inhibitory action of a phenothiazine derivative on the hexosemonophosphate dehydrogenases of adrenal cortex. Arch Biochem Biophys. 1961 Nov; 95:192-6. PMID: 14470052.
        View in: PubMed
      James's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP